Care is Primary: Practical Tips for Everyday Practice
from Partners in Progressive Medical Education
Tirzepatide in Focus: Translating SURPASS-CVOT Findings into Patient Care
In this episode of Care is Primary, we unpack the results of the landmark SURPASS-CVOT trial, presented at EASD 2025, and explore what the findings mean for primary care.
We’re thrilled to be joined by cardiologist Dr. Grace Chua, who brings expert insights into cardiovascular outcomes and diabetes care. Along with hosts Drs. James Kim and Akshay Jain, this dynamic conversation dives into the groundbreaking first-ever head-to-head cardiovascular outcomes trial comparing tirzepatide, a dual GIP/GLP-1 receptor agonist, with dulaglutide, a GLP-1 receptor agonist.
Together, they unpack:
• How the REWIND trial set the stage for SURPASS-CVOT
• Key findings from the SURPASS-CVOT study at EASD 2025
• How to choose the right patients in your clinic to optimize patient outcomes
• How SURPASS-CVOT could transform future diabetes and cardiology guidelines
• How the REWIND trial set the stage for SURPASS-CVOT
• Key findings from the SURPASS-CVOT study at EASD 2025
• How to choose the right patients in your clinic to optimize patient outcomes
• How SURPASS-CVOT could transform future diabetes and cardiology guidelines
This is a must-listen episode for primary care providers, endocrinologists, and cardiologists who want to stay ahead of the curve in cardiovascular risk management for type 2 diabetes.